Oral News and Research

RSS

GI Dynamics announces data on EndoBarrier therapy for type 2 diabetes, obesity

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced data with the EndoBarrier Gastrointestinal Liner at 12 months showing significant weight loss and cardiovascular and metabolic improvements in obese patients.

7 Sep 2010

Plaque-causing bacteria increases risk of heart attack

Plaque-causing bacteria can jailbreak from the mouth into the bloodstream and increase your risk of heart attack says a scientist at the Society for General Microbiology's autumn meeting in Nottingham.

6 Sep 2010

Single-dose of experimental malaria drug clears parasites in mice, represents potential new class of drugs to treat malaria in humans

An experimental malaria drug was shown to effectively treat the disease in mice with only a single dose, according to a study published Thursday in the journal Science, Reuters reports (Kelland, 9/2). The new drug, known as NITD609, "represents an entirely new class of medicines to treat malaria ... Human trials, backed by Swiss pharmaceutical giant Novartis AG, could begin later this year," the Wall Street Journal writes (Naik, 9/3).

4 Sep 2010

AVAC calls for economic and political support for CAPRISA 004 microbicide trial's critical follow-up studies

AVAC today issues a call to action to donors, policy-makers, researchers and advocates to ensure that critical follow-up studies to the landmark CAPRISA 004 microbicide trial receive the economic and political support needed to move forward as quickly as possible. The call comes as a group of microbicide and public health experts have agreed upon a plan for further studies, which are expected to cost $100 million over three years, of which only $58 million has been committed.

4 Sep 2010

European Menopause and Andropause Society's position statements on post-reproductive health of women

Elsevier announced today the publication of four important position statements from the European Menopause and Andropause Society (EMAS) in the journal Maturitas on common management problems in the post-reproductive health of women. The statements cover the management of the menopause in the context of obesity, epilepsy, endometriosis and premature ovarian failure. Each statement has summary recommendations as a quick aid for the busy clinician.

3 Sep 2010

Researchers discover novel compound to combat drug resistant malaria

Novartis announced today that scientists at the Novartis Institute for Tropical Diseases (NITD), in collaboration with researchers from the Genomics Institute of the Novartis Research Foundation (GNF), the Swiss Tropical and Public Health Institute and The Scripps Research Institute have discovered a novel compound that shows promise as a next generation treatment for drug resistant malaria.

3 Sep 2010

Transdel Pharmaceuticals presents Ketotransdel Phase 3 data at 13th World Pain Congress

Transdel Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, announced today the final data set from its Phase 3 study of Ketotransdel® (TDLP-110) at the 13th World Congress on Pain in Montreal, Canada.

2 Sep 2010

Dietary supplement combining zinc, phytase enhances effectiveness of BTX injections: Study

Taking a dietary supplement of organic zinc and the enzyme phytase four days before receiving botulinum toxin injections made the toxin more effective in 93 percent of patients tested in a recent study at The Methodist Hospital in Houston.

2 Sep 2010

Survey: 65% of parents look to schools to help reinforce importance of oral health

Two-thirds (65%) of parents are looking to schools to help reinforce the importance of oral health, saying it is extremely or very important for schools to teach children about taking care of their teeth, according to a new public opinion survey commissioned by Oral Health America.

2 Sep 2010

XARELTO achieves net clinical benefit in treatment of patients with DVT

Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.

2 Sep 2010

Inhibitex completes INX-189 Phase1a trial for HCV

Inhibitex, Inc., announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo. The Company plans to present detailed results from this trial during a future scientific meeting.

2 Sep 2010

Pfizer enters agreement to acquire FoldRx Pharmaceuticals

Pfizer Inc. and FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company, today announced that they have entered into an agreement under which Pfizer will acquire FoldRx.

2 Sep 2010

SAMe dietary supplement effective for major depressive disorders: Study

A new study conducted by investigators at Harvard Medical School and Massachusetts General Hospital (MGH) suggests that S-Adenosyl Methionine (SAMe), an over-the-counter dietary supplement, can be an effective, relatively well-tolerated, adjunctive treatment for adults with major depressive disorders who do not respond to their treatment with antidepressant medication.

2 Sep 2010

Indiana reports fewer preventable medical errors; Kansas struggles to meet oral health needs

The Indianapolis Star: "Indiana's hospitals and ambulatory surgery centers reported a decrease in preventable medical errors last year -- including a 33 percent drop in the number of bed sores. Overall, 306 facilities reported 94 preventable medical errors in 2009, according to a report released Monday by the Indiana State Department of Health. That's down from 105 errors reported each year in 2008 and 2007. The 22 pressure ulcers, also called bed sores, reported for 2009 were the fewest since the state's medical-error reporting system began four years ago" (Lee, 8/31).

2 Sep 2010

Study to determine how often chronic Lyme disease is diagnosed and treated

A study soon to be published in The Journal of Pediatrics attempts to determine how often chronic Lyme disease is actually being diagnosed and treated.

2 Sep 2010

Event Pulse report reveals impact of new therapies on MS drug market

The study titled Event Pulse Preview: Multiple Sclerosis shows that 84% of neurologists expect to prescribe Gilenia for some MS patients if approved, but prescribing will likely be limited to second- or third-line therapy until concerns about safety and monitoring requirements are resolved.

1 Sep 2010

ESC issues revised practice guidelines for management of AF

The European Society of Cardiology today issued revised practice guidelines for the management of atrial fibrillation, including guidance on the role of a novel oral treatment, dabigatran etexilate, for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

31 Aug 2010

Phase 3 EINSTEIN-DVT clinical trial data can transform deep vein thrombosis treatment

Johnson & Johnson Pharmaceutical Research & Development, announced today that the investigational, oral anticoagulant rivaroxaban successfully demonstrated non-inferiority compared to the standard of care for the prevention of recurrent venous thromboembolism (VTE) in patients with acute symptomatic deep vein thrombosis (DVT), with a comparable safety profile.

31 Aug 2010

Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study

Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic osteoarthritis knee pain have been published by Clinical Drug Investigation.

31 Aug 2010

Forensic Fluids Laboratories ranked #167th on Inc. 500 fastest growing companies list

Forensic Fluids Laboratories Inc., a leading provider of oral fluid drug testing, today announced that the company was named to the prestigious Inc. 500 list, a list of the most entrepreneurial and fastest growing companies in the United States. Forensic Fluids Lab was number 167 on the general list, number 10 in health care, number 2 in Michigan, and number 20 for women-owned.

31 Aug 2010

Oral News and Research

GI Dynamics announces data on EndoBarrier therapy for type 2 diabetes, obesity

Plaque-causing bacteria increases risk of heart attack

Single-dose of experimental malaria drug clears parasites in mice, represents potential new class of drugs to treat malaria in humans

AVAC calls for economic and political support for CAPRISA 004 microbicide trial's critical follow-up studies

European Menopause and Andropause Society's position statements on post-reproductive health of women

Researchers discover novel compound to combat drug resistant malaria

Transdel Pharmaceuticals presents Ketotransdel Phase 3 data at 13th World Pain Congress

Dietary supplement combining zinc, phytase enhances effectiveness of BTX injections: Study

Survey: 65% of parents look to schools to help reinforce importance of oral health

XARELTO achieves net clinical benefit in treatment of patients with DVT

Inhibitex completes INX-189 Phase1a trial for HCV

Pfizer enters agreement to acquire FoldRx Pharmaceuticals

SAMe dietary supplement effective for major depressive disorders: Study

Indiana reports fewer preventable medical errors; Kansas struggles to meet oral health needs

Study to determine how often chronic Lyme disease is diagnosed and treated

Event Pulse report reveals impact of new therapies on MS drug market

ESC issues revised practice guidelines for management of AF

Phase 3 EINSTEIN-DVT clinical trial data can transform deep vein thrombosis treatment

Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study

Forensic Fluids Laboratories ranked #167th on Inc. 500 fastest growing companies list

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News